Schrödinger Q2 2024 Earnings Report $19.96 -0.30 (-1.48%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Schrödinger EPS ResultsActual EPS-$0.74Consensus EPS -$0.85Beat/MissBeat by +$0.11One Year Ago EPSN/ASchrödinger Revenue ResultsActual Revenue$47.33 millionExpected Revenue$40.19 millionBeat/MissBeat by +$7.14 millionYoY Revenue GrowthN/ASchrödinger Announcement DetailsQuarterQ2 2024Date7/31/2024TimeN/AConference Call ResourcesSDGR Earnings History Remove Ads Schrödinger Earnings HeadlinesSchrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth PlansMarch 27 at 10:41 AM | finance.yahoo.comSchrödinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Buy" by BrokeragesMarch 27 at 2:39 AM | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.March 29, 2025 | Paradigm Press (Ad)Schrödinger to Present Preclinical Data at AACR Annual MeetingMarch 25, 2025 | finance.yahoo.comSchrödinger beruft Bridget van Kralingen in den VorstandMarch 10, 2025 | de.investing.comSchrödinger Expands Board of Directors with Appointment of Bridget van KralingenMarch 10, 2025 | finance.yahoo.comSee More Schrödinger Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Schrödinger? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Schrödinger and other key companies, straight to your email. Email Address About SchrödingerSchrödinger (NASDAQ:SDGR), together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.View Schrödinger ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
